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Abetalipoproteinemia (ABL) is an extremely rare disease with only 100 cases 
approximately reported in the clinical literature worldwide. Virtually absent 
apolipoprotein B-containing lipoproteins, extremely low vitamin E levels, steatorrhea, 
and acanthocytosis are hallmarks of this disorder. 
ABL is a Mendelian metabolic disorder caused by mutations in the MTTP gene encoding 
the microsomal triglyceride transfer protein large subunit, that lead to a truncated 
protein. Deficiency of MTTP hinders the production of apolipoprotein B-containing 
lipoproteins, leading to virtually absent levels of LDL, and VLDL and chylomicrons. The 
malabsorption of lipids and fat-soluble vitamins A, D, E, and K is linked to a series of 
gastrointestinal, neurological, ophthalmological, and hematological clinical 
manifestations. Lifetime monitorization and symptomatic treatment with fat-soluble 
vitamins and the implementation of a fat-restrictive diet reduces the morbimortality in 
affected individuals. High-dose vitamin E (50-300 IU/kg/day) and vitamin A (100–400 
IU/kg/day) is required to prevent or even reverse neurological and retinal degeneration, 
respectively. In addition, supplementation of other nutrients and fat-soluble vitamins D 
and K might be necessary to treat the vast spectrum of clinical manifestations present 
in ABL. 
There is currently only symptomatic treatment for ABL. However, in the last few years, 
new personalized gene therapies using CRISPR/Cas9 gene edition and other approaches 
have been started to be investigated to treat rare genetic disorders. Therefore, a 
potentially curative treatment could be developed in the future. 
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L’abetalipoproteïnèmia (ABL) és una malaltia genètica extremadament rara, amb 
aproximadament només 100 casos descrits a la literatura clínica en tot el món. 
L’absència pràcticament total de lipoproteïnes carregades d’apolipoproteïna B, els 
nivells extremadament baixos de vitamina E, l’esteatorrea i l’acantocitosi són les 
característiques més distintives d’aquesta patologia.  
L'ABL és un trastorn metabòlic mendelià causat per mutacions en el gen MTTP codificant 
de la subunitat gran de la proteïna microsomal transportadora de triglicèrids, donant 
lloc a una proteïna truncada. La deficiència de MTTP dificulta la producció de 
lipoproteïnes que contenen apolipoproteïna B, fet que condueix a nivells pràcticament 
absents de LDL i VLDL i quilomicrons. La malabsorció de lípids i vitamines liposolubles A, 
D, E i K està relacionada amb una sèrie de manifestacions clíniques gastrointestinals, 
neurològiques, oftalmològiques i hematològiques. El seguiment i el tractament 
simptomàtic amb vitamines liposolubles i la implementació d’una dieta restrictiva de 
greixos al llarg de tota la vida redueixen la morbiditat i la mortalitat en les persones 
afectades. El tractament amb dosis elevades de vitamina E (100-300 UI /kg/dia) i 
vitamina A (100-400 UI/kg/dia) és un requeriment per tal de prevenir o, fins i tot revertir, 
la degeneració neurològica i de la retina, respectivament. Pot ser necessària la 
suplementació d’altres nutrients i de vitamines liposolubles D i K per tractar el vast 
espectre de manifestacions clíniques presents en l’ABL. 
Actualment, només hi ha tractament simptomàtic per a l’ABL. No obstant això, en els 
darrers anys s’han començat a investigar noves teràpies gèniques personalitzades que 
utilitzen l’edició gènica amb CRISPR/Cas9 i altres tècniques per tractar trastorns genètics 
rars. Això representa  un potencial tractament curatiu que podria desenvolupar-se en el 
futur. 
Paraules clau: abetalipoproteïnèmia · lipoproteïna B · lipoproteïna de baixa densitat · 













INTEGRATION OF FIELDS 
This Bachelor's Degree Final Project encompasses three major disciplines, the main area 
being Physiology & Physiopathology. Secondary disciplines are Biochemistry & 
Molecular biology, and Pharmacology & Therapeutics. 
• The main focus of the study covers the fields of Physiology & Physiopathology. 
Physiology studies the organs and their functioning in a normal state of health, 
while pathophysiology is the analysis of the organism in a pathological state. A 
substantial part of the project consists of observing the clinical manifestations in 
different organ systems caused by an alteration in the absorption of lipids 
(including fat-soluble vitamins) in abetalipoproteinemia and making an accurate 
diagnosis from it. 
• Biochemistry & Molecular biology are two areas of study required to explain the 
structure and the role of MTTP at a molecular level and how mutations in the 
encoding gene lead to a defective protein, impeding the trafficking and 
formation of apo b-containing lipoproteins.  
• Last but not least, Pharmacology & Therapeutics are two medical disciplines 
indispensable to explain the current treatment of abetalipoproteinemia and 
even hint at a feasible new therapeutic approach. 






















1.1. RARE DISEASES 
The European Organization for Rare Diseases (EURORDIS) categorizes the rare diseases, 
as well as the neglected diseases –which are most prevalent in developing countries, but 
not in the industrialized world– as orphan diseases, due to the disinterest of public 
health policies as well as of the pharmaceutical industry in their market, as it is generally 
seen as unprofitable (1). 
A rare disease is a disease that affects a reduced number of people. The exact definition 
varies depending on the geographical area: while in Europe a disease is considered rare 
when it affects fewer than 1 in 2,000 inhabitants, in the United States its occurrence 
must be less than 200,000 individuals. To date, more than 8,000 rare diseases have been 
recognized, 80% of which are genetic disorders. Alterations of a single gene are termed 
Mendelian or monogenetic diseases and make up a significant proportion of the genetic 
disorders,  affecting approximately 1 out of 50 individuals in Europe (2). 
Rare diseases have some common traits: they usually appear  at birth or in childhood, 
are incurable and chronic, usually degenerative and potentially life-threatening. In 
addition, they cause a tremendous psychosocial burden on the patients and their 
families, that lack hope in finding a suitable therapy or even getting the proper diagnosis 
(1). Because of those characteristics, it is essential to make an early diagnosis to lessen 
long-term complications and receive early treatment, if possible. 
New diagnostic approaches such as next‐generation sequencing have allowed the 
diagnosis of many rare genetic diseases to be made within just a few weeks. Most rare 
genetic disease variants are caused due to mutations in coding regions of the genome. 
Thus, whole-exome sequencing (WES) as a diagnostic method is currently a common 
and appropriate approach. However, whole-exome sequencing is insufficient in 
understanding the role of structural and noncoding region variants. So complementary 
techniques, such as whole-genome sequencing (WGS), are used to target those variants 
efficiently. Improvements in the area of bioinformatics are still required to facilitate the 









1.2. ABETALIPOPROTEINEMIA AS A RARE DISEASE 
Abetalipoproteinemia (ABL) is an extremely rare autosomal recessive genetic disease 
with an unknown prevalence but estimated to be less than 1 / 1,000,000 (4). It was firstly 
described in a Jewish girl in 1950 (5), and up to date, approximately 100 cases have been 
published in the clinical literature worldwide (6). Affected individuals are biallelic 
homozygotes or compound heterozygotes for MTTP mutations that lead to a 
nonfunctional MTTP protein, hampering its activity in the trafficking of lipids and the 
assembly and secretion of lipoproteins containing apolipoprotein B (7).  
The onset of the disease is usually at birth or in early childhood. Without an accurate 
vitamin supplementation, neurological and retinal degeneration can drastically 
decrease the patient’s quality of life (8).  
Diagnosis has improved a lot through the years, as more cases have been described. 
Next-generation sequencing (NGS) strategies are currently used to identify mutations in 
the MTTP gene to obtain a proper diagnosis of the disease. 
Like most rare diseases, few studies about abetalipoproteinemia have been performed, 
and no specific, curative, and/or etiological treatment has been developed. 
Symptomatic treatment involving a low-fat diet and oral or parenteral fat-soluble 


















Abetalipoproteinemia is an extremely rare metabolic disease that was discovered just 
seven decades ago. There is currently no curative treatment available, although its study 
served as a basis for developing a drug to treat familial hypercholesterolemia. The only 
existing treatment consists mainly of a fat-restricted diet along with vitamin 
supplementation. 
The fact that a close relative of mine has that disease is what motivated myself to do 
this bachelor’s degree final project about such an unknown condition. I believed that by 
searching and studying about ABL, I would get a better understanding of the disease and 
apply the knowledge to help this person. 
The project’s general aim is to carry out an extensive and up-to-date bibliographic 
review of various aspects related to the disorder to serve as a guide or manual for 
healthcare professionals, affected individuals and their families. 
In this fashion, the specific objectives of the work can be grouped into three blocks: 
• The study of the origin of the disease by delving into its history and epidemiology 
and how the knowledge regarding ABL has advanced from 1950, when a case was 
documented for the first time, until now.  
• The understanding of the etiology and pathogenesis of this rare genetic disease 
which leads to a myriad of clinical manifestations in several organ systems. 
• A report on aspects of more clinical relevance: the diagnosis, the follow-up and 
monitoring of parameters that may be affected; the prognosis of the disorder; and 









The topic of the project was proposed by myself because of personal motivation, as I 
have a close relative who suffers from abetalipoproteinemia. 
Initially, I relied on the knowledge I had acquired about the disorder thanks to closely 
observing a patient with ABL by examining who is involved in the interprofessional team, 
what follow-up and treatment he has received, etc. Thus, from that basis, I designed the 
structure of the project. 
After I had the body of the project, I realized the bibliographic research, which consisted 
of two parts: 
• The study of recent literature reviews and research articles published in the last 
seven years (from 2014 to 2021) in Scopus and PubMed, using, in some instances, 
Boolean operators: e.g., “Abetalipoproteinemia AND (Vitamin E OR Ataxia)”, 
“Abetalipoproteinemia AND MTTP”, “Atypical retinitis pigmentosa AND Vitamin A”. 
Then, I tried discerning the most reliable information by looking at the authors’ 
publications, the scientific journal. 
• A compendium of clinical cases gathered from PubMed, Scopus, and Google Scholar, 
placing particular emphasis on the oldest cases reported. The main purpose was to 
observe and compare the diagnosis and treatment received by patients in the 50s to 
the 70s with that received in the present day, as well as identifying all clinical 
manifestations described in patients with ABL. I reviewed several clinical cases and 
selected those that contained the most relevant information. 
 
It is to be noted that there is no extensive bibliographic material regarding ABL, since 









4. RESULTS AND DISCUSSION 
4.1. EPIDEMIOLOGY AND HISTORY OF ABETALIPOPROTEINEMIA 
Prank A. Bassen and Abraham L. Kornzweig described for the first time in 1950 a case of 
abetalipoproteinemia (ABL). The reported patient was an 18 years old Jewish female girl 
born of consanguineous parents exhibiting a form of Friederichs’s ataxia and an atypical 
type of retinitis pigmentosa. She had steatorrhea from childhood. Unexpected findings 
revealed abnormal red blood cells (RBCs) that took on bizarre shapes similar to crenated 
cells with protuberances that looked like buds or pseudopods. Such shapes of RBCs were 
never reported before. Her 9 years old brother also suffered from retinitis pigmentosa 
and the same malformation of red cells (5).  In 1952, Singer, Fisher & Perlstein reported 
another case of a 13 years old Jewish boy who presented with ataxia, loss of all deep 
tendon reflexes, and the same characteristic aberrant RBCs. They termed those 
abnormal red blood acanthrocytes (akantha, “thorn” in Greek) in accordance with their 
spiculated or thorny morphology (9). Later, Druez renamed the condition 
acanthocytosis, without the “r” (10). The disease was initially named as Bassen-
Kornzweig syndrome, taking the name of the two doctors who first described it and was 
later referred to as abetalipoproteinemia by Salt et al  in 1960(11). 
All early cases reported of ABL were of Jewish individuals. Furthermore, a study made 
by Liat Benayoun et al. in 2006 found evidence for a founder nonsense mutation in the 
MTTP gene, p.G865X, in three unrelated Ashkenazi Jewish families probands, that 
caused the substitution of a codon for glycine at position 865 for a stop codon (12). 
Afterward, they found the presence of the mutation p.G865X in 3 of 786 Ashkenazi 
Jewish control genomes, suggesting an estimated prevalence of 1/ 69,000 in this 
population. 
More than 100 new cases of abetalipoproteinemia caused by at least 74 pathogenic 
MTTP variants  have been described since 1950, allowing improvements in diagnosis, 
monitoring, and treatment (13). Implementation of a restrictive lipid diet, a combination 
of fat-soluble vitamins A and E (plus vitamin D and K if needed), and medium-chain 
triglycerides (MCT) has led to an incredible amelioration of the clinical manifestations, 
including gastrointestinal, neuromuscular, and ophthalmic symptomatology (14). A 
summary of the most conspicuous events and discoveries regarding 








Figure 1: Chronological diagram of findings on abetalipoproteinemia and related events. Own 
creation. 
4.2. ETIOLOGY AND PATHOGENESIS 
ABL is a disorder caused by mutations in the MTTP gene that lead to a non-functional 
protein with an absent large microsomal triglyceride transfer protein (MTTP) subunit, 
an essential cofactor for the production of apolipoprotein B (apo B)-containing 
lipoproteins in the liver and the intestines (15). The defective MTTP chaperone hampers 
the transference of lipids (triacylglycerols, cholesterol esters, and phospholipids) onto 
the newly synthesized apo B, as well as the correct assemble and secretion of apo B-
containing lipoproteins, leading to a virtual absence of circulating apo B, and 
subsequently impeding the production of apo B-containing lipoproteins chylomicrons, 
LDL or VLDL (7), as illustrated in Figure 2. 
 
Figure 2: Representation of the consequences of a defective MTTP protein for the production of 







4.2.1. FORMATION OF APO B-CONTAINING LIPOPROTEINS 
Apolipoprotein B-containing lipoproteins (B-lps) are macromolecular micelles composed 
of a hydrophilic surface monolayer of phospholipids with free cholesterol and 
apolipoproteins, especially apo B; and a hydrophobic neutral lipid core that contains 
triacylglycerols (TG), cholesteryl esters, and fat-soluble vitamins (16).  
The two forms of apolipoprotein B apo B-100 and apo B-48 are polypeptides of different 
sizes derived from a unique mRNA transcribed from the APOB gene. The APOB mRNA in 
enterocytes is edited posttranscriptionally by the enzyme apobec-1 generating a stop 
codon that makes the polypeptide produced to be 52% shorter than the unedited apo 
B-100 of the hepatocytes. Hence, the truncated apo B in the intestine is named apo B-
48 (because it has 48% of the total length of apoB100) (17). ApoB48 in the intestine 
allows the entrance of long-chain triglyceride (TG) and fatty acids into chylomicrons 
(CM)(18), whereas in the liver, apo B-100 assists in the synthesis of very low-density 
lipoprotein (VLDL), and its metabolic products intermediate-density lipoprotein (IDL) 
and low-density lipoprotein (LDL) (8)(19). 
The assembly of apo B-containing lipoproteins is a two-step process that begins with the 
synthesis of phospholipids and triacylglycerols in the RE and the interaction of the βα1 
domain of nascent apo B peptides with the inner phospholipid monolayer to form 
nucleation sites for the assembly of lipoproteins.  
The phospholipids are transferred to the nascent apo B due to the chaperone activity of 
the MTTP protein which also interacts with the βα1 domain of apo B, aided by cell death-
inducing DFF45-like effector B (CIDEB) and by phospholipid transfer protein (PLTP) (PLTP 
assists, but is not critical for the assembly of intestinal lipoproteins), and triacylglycerols 
enter via lateral diffusion within the ER membrane. Contrary to CIDEB and PLTP, which 
facilitate the addition of triglycerides in the nascent apo B, ancient ubiquitous protein 1 
(AUP1) inhibits the process. Thus, the lipidation process gives rise to small sized 
primordial B-lps that at some point detach from the ER membrane and become lumenal 
particles.  
The second step begins once the primordial lipoprotein is formed. It undergoes a core 
expansion, which involves bulk addition/the addition of large amounts of lipids from apo 
B-free lumenal lipid droplets (LDs) in the ER by membrane fusion to primordial B-lps. 
MTTP has been found to have a role in the formation of ER lumenal LDs from 
hepatocytes and enterocytes as well as facilitating the fusion of primordial B-lps and 







Figure 3 summarizes the role of lipid transfer proteins, including MTTP, in the assembly 




Figure 3: Schematic illustration of the role of lipid transfer proteins in the assembly of apoB-
containing lipoproteins. Taken from: Lipid transfer proteins in the assembly of apoB-containing 
lipoproteins (16). 
Other exchangeable apolipoproteins, like apo E, apo C-III, and apo A-IV, may assist in 
their assembly to stabilize the surface of these large lipoproteins. The newly synthesized 
lipoproteins dissociate from MTTP to allow them to exit the RE lumen, followed by 
recognition on apo B by coat-protein complex II (COPII) for selective transport. 
Finally, the nascent B-lps are transported by specialized vesicles (pre-chylomicrons and 
pre-VLDL transport vesicles) to Golgi apparatus and secreted to export fat to other 









4.2.2. MUTATION IN MTTP: INHIBITION OF MTTP IN ABL  
The heterodimeric functional microsomal triglyceride transfer protein is an essential 
element for the assembly and secretion of the apolipoprotein B-containing lipoproteins 
chylomicrons (CM), very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), 
and intermediate-density lipoprotein (IDL). Its cellular localization in the lumen of the 
RE and Golgi apparatus of enterocytes and hepatocytes explains the gastrointestinal and 
hepatic manifestations in the disorder. It is composed of a large ~ 97-kDa microsomal 
triglyceride transfer protein (MTTP) subunit, a single peptide of 894 amino acid encoded 
by MTTP gene located on chromosome 4q23); and a ~ 55-kDa ubiquitously expressed 
protein disulfide isomerase (PDI) encoded by P4HB (8). Figure 5 shows the genomic 
location of the human MTTP gene. 
 
 
Figure 4: MTTP Gene in genomic location: bands according to Ensembl, locations according to 
GeneLoc. Taken from The Human Gene Database GeneCards (20)  
The non-covalent interactions of the M large subunit with the PDI subunit generate the 
active lipid transfer complex. Figure 4 shows the superficial structure of the MTTP 
heterodimer. While PDI maintains the solubility of the dimer and facilitates the 
formation of disulfide bonds of nascent proteins, its activity is not essential for the 
assembly of apo B-containing lipoproteins (21). In contrast, mutations in the MTTP gene 
encoding M large subunit were identified to be responsible for the etiology of ABL 
disorder (7) since apo B-containing lipoproteins (CMs and VLDLs) cannot be synthesized 
in the absence of MTTP (and/or lipids) as they need apoB45 and apoB100 respectively 
for their formation, which contains lipids transferred by MTTP. Likewise, the role of 
MTTP on the transportation of triglycerides to the ER is also essential to form apo B-free 
lipid droplets that fuse with nascent apo B-containing particles to yield mature B-lps 
(22). Subsequently, the lack of MTTP gives rise to misfolded polypeptides that end up 








Figure 5: 3D structure of the heterodimeric active MTTP complex showing the surface of its two 
subunits: MTTP large subunit (in blue) and PDI small subunit (in orange). PDB ID: 6I7S. 
Up to date, at least 74 mutations leading to totally absent or defective, truncated MTTP 
(mostly deletions, substitutions, and frameshifts, including missense, nonsense, and 
splice-site mutations) have been found in approximately 100 affected individuals (13). 
Following an autosomal recessive transmission of the disease, probands are either 
homozygotes or compound heterozygotes for MTTP mutations (4). 
4.3. CLINICAL MANIFESTATIONS 
ABL is an extremely rare disease. Therefore, it is difficult to predict its course due to the 
lack of cases reported. 
The hallmarks of the disease are the virtually absent apo B-containing lipoproteins, 
including chylomicrons, VLDL, and LDL (below the 5th percentile); the presence of 
acanthocytes in blood smear; steatorrhea (foul-smelling stool); and extremely low 
vitamin E levels (24). 
At birth, patients with ABL are asymptomatic (25). The onset of the symptoms generally 
occurs in the first few months of life due to the resultant malnutrition and malabsorption 
of fats, essential fatty acids (EFAs), and liposoluble vitamins (A, D, E, K) (4). 
4.3.1. GASTROINTESTINAL MANIFESTATIONS 
The first symptom to appear is steatorrhea, often accompanied by other digestive 







Gastrointestinal impairments are the most common manifestations in childhood. With 
restrictiveness in the consumption of fatty aliments, the manifestations diminish but 
reappear when the diet is not followed. Fat malabsorption results in severe malnutrition 
if a specific low-fat diet is not implemented. 
4.3.2. HEPATIC MANIFESTATIONS 
Hepatic alterations appear because of an accumulation of lipids (triglycerides) in the 
liver (27). Liver disorders tend to be severe but are unusual. Fatty liver disease, hepatic 
steatosis, and hepatomegaly have been reported several times (27,28). Hepatocellular 
carcinoma (29), cirrhosis, and hepatic fibrosis have also been described in patients with 
abetalipoproteinemia although very seldom. Administration of MCT, especially in long-
term therapy, has been found to exacerbate cirrhosis and hepatic fibrosis (30,31). 
Liver transplantation corrects serum lipoprotein levels. However, defective MTTP 
remains expressed in the intestines, impeding the absorption of fats (32). 
4.3.3. HEMATOLOGICAL MANIFESTATIONS 
Acanthocytosis, a “burr-cell” malformation of red blood cells (RBCs), is observed in >90% 
of cases, comprising 50% to 100% of circulating RBCs. Acanthocytes appear to have an 
abnormal spiculated star-shaped morphology. Figure 6 shows acanthocytes from a 
blood smear of a patient with ABL). Other less prevalent hematological findings are 
anemia due to iron or folic acid deficiencies, reticulocytosis, hemolysis with resultant 
hyperbilirubinemia, and abnormal bleeding due to prolonged INR caused by vitamin K 
deficiency (4,8,26).   
  
Figure 6: Peripheral blood film of a patient with ABL showing multiple acanthocytes. Taken 







4.3.4. NEUROMUSCULAR MANIFESTATIONS 
ABL patients may present in the first or second decade of life with neurodegenerative 
manifestations secondary to vitamin E deficiency associated with demyelination of 
spinocerebellar axons (34,35). Neuromuscular manifestations can greatly impact on the 
quality of life of the patients and symptoms include delayed intellectual development,  
lack of coordination,  nystagmus,  muscle weakness, muscle degeneration, and 
peripheral neuropathy as there is a progressive loss of deep tendon reflexes, 
proprioception, and vibration sense. Myositis has also been described in a patient with 
elevated levels of muscle enzymes (36). Eventually, if left without intervention, 
Friedrich's-like ataxia, a severe neuromyopathy, can develop in early adulthood. To 
prevent or delay the development of neurological dysfunctions, early treatment with 
excess vitamin E is shown to be effective (4,36).  
4.3.5. OPHTHALMOLOGICAL MANIFESTATIONS 
Ophthalmological symptoms usually appear in adulthood due to vitamin A deficiency, 
the most prominent being an atypical retinitis pigmentosa that commonly begins with a 
loss of night vision or loss of color vision, which progresses to expanding scotomas and 
can eventually result in complete blindness if untreated (4).  
Other less frequent ocular findings include ptosis and ophthalmoplegia which are 
thought to appear as a result of cranial nerve demyelination caused by vitamin E 
deficiency (8), as well as bilateral swelling of the optic discs (37) and corneal ulcers due 
to dysfunction of the lacrimal glands caused by vitamin A deficiency (4). 
4.3.6. OTHER MANIFESTATIONS  
Individuals with abetalipoproteinemia have an extremely reduced risk of suffering from 
many heart and vascular diseases, such as atherosclerosis and thrombosis, due to the 
absence of LDL cholesterol and low triglycerides levels.  
Cardiac and endocrinologic manifestations are rare, albeit cardiomegaly and 
cardiomyopathy, as well as hypothyroidism (38), have been reported to occur in some 
patients later in life (8).  
Rickets, osteopenia, and other bone findings have been observed as consequences of 
vitamin D and calcium malabsorption (39,40). 
Table 1 compiles a list of clinical manifestations that have been selected by the Human 








Table 1: Clinical manifestations of abetalipoproteinemia classified by frequency. 
Adapted from database HPO (40). 






Low levels of vitamin E 
Steatorrhea 

















Low levels of vitamin A 
Low levels of vitamin D 
Myalgia 
Nyctalopia 
































































Untreated patients typically suffer from neurological and ophthalmological 
degeneration, rarely  surviving past the second or third decade of life (8). However, 
individuals treated with life-long high doses of fat-soluble vitamins and a special low-fat 
diet present few complications, and cases of individuals living until the seventh and 
eighth decade of life with no significant repercussion in their quality of life and life 
expectancy have been reported (41).  
4.4. DIAGNOSIS 
Due to the rarity of the disease, probands are often initially misdiagnosed, taking years, 
or even a life-time, to be properly diagnosed. This fact can have severe consequences 
for individuals with ABL, because without the diagnosis they do not receive the vitaminic 
supplements needed. Subsequently, these patients end up having severe symptoms, 
especially neurodegenerative spinocerebellar ataxia and myopathy beginning in the 
second decade of life due to vitamin E deficiency and ophthalmological problems due to 
vitamin A deficiency. 
There is no established guideline for the diagnosis of ABL, and typically diverse 
diagnostic methods are used to identify the disorder. Firstly, symptomatic 
manifestations are observed, but this alone often leads to erroneous diagnoses. 
Furthermore, because ABL is a rare disorder, it may be necessary to do a differential 
diagnosis, eliminating possible pathologies by observing the symptoms and discovering 
the signs via laboratory investigations.  
Before reaching the definitive diagnosis, probands are usually diagnosed based mainly 
on the symptoms observed, which can differ depending on the age of the proband. It is 
vital to identify all manifestations, as the recognition of the pathology is strongly based 
on differential diagnoses. Hence, precise identification of the clinical features will 
shorten the list of possible disorders. However, whereas an observational study of 
manifestations can be helpful to identify typical cases of ABL, it might hinder the 
detection of atypical ABL, in which less common symptoms, such as vomiting or 
hypothyroidism (38), can mistakenly induce the exclusion of ABL as a diagnosis before 
reaching laboratory investigations. 
Young patients with steatorrhea, diarrhea, and failure to thrive tend to be erroneously 
diagnosed at first with malabsorption syndromes, such as lactose intolerance in 
breastfeeding patients, or celiac disease when they grow up (25,42). Nevertheless, even 
after implementing a gluten-free or lactose-free diet, symptoms do not diminish, and 







Adult patients who have learned to follow a restrictive lipid diet, but do not take fat-
soluble vitamin supplements, are prone to develop degenerative neuromuscular 
manifestations that may lead to an incorrect diagnosis of Friedrich’s ataxia, McLeod 
syndrome, or isolated vitamin E deficiency (4).  An atypical form of retinitis pigmentosa 
is another prominent manifestation caused by deficiencies in vitamin A and vitamin E 
levels. 
After the evaluation of symptoms, signs are investigated. Laboratory screenings are 
performed to justify the patient's overall symptomatology and obtain analytical results 
to reach a differential diagnosis and adequately identify the disease. For example, the 
study of stools shows steatorrhea, indicating fat malabsorption. Endoscopy in patients 
who do not follow a lipid-restrictive diet may show the intestinal mucosa to have a 
"gelee blanche" or "white hoar frosting" appearance. Moreover, intestinal epithelium 
biopsy may show enlarged enterocytes with a clarified cytoplasm full of intracellular 
neutral lipid (4). 
Hematologic tests allow the identification of acanthocytosis in blood smear. At least 50% 
of the total account of red blood cells are acanthocytes, which are abnormally spiked 
and usually star-shaped. In addition, extremely low erythrocyte sedimentation rates are 
detected due to their structure (34). Along with the neurological findings, this might 
prompt consideration of other neuroacanthocytosis, such as McLeod syndrome (43).  
Less frequently, reticulocytosis, hemolysis, hyperbilirubinemia, and anemia can be 
found in ABL patients (26,44).  
The lipidic study of probands and their parents allows for a differential diagnosis of 
hypobetalipoproteinemia, including ABL, FHBL, combined hypolipidemia, and 
chylomicron retention disease (CRD). Figure 7 schematizes the etiology of genetic 









Figure 7: Differential diagnosis of abetalipoproteinemia compared to other 
hypolipoproteinemias. Adapted from: Genetic Abetalipoproteinaemia and 
Hypobetalipoproteinaemia (45), and Guidelines for the diagnosis and management of 
chylomicron retention disease based on a review of the literature and the experience of two 
centers (46).  
The lipid profile of probands with ABL or homozygote/compound heterozygote FHBL 
(caused by mutations in APOB) show a virtually absent plasma VLDL-C, LDL-C (<0.1 
mmol/L), and apo B (<0.1 mg/dL, < 5th percentile), very low  triglyceride levels (fasting 
TG <0.2 mmol/L), and a marked hypocholesterolemia (total plasma cholesterol levels 
usually < 0.8 mmol/L or <50 mg/dL). A complete lipid profile screening is not required 
for diagnosis as the observation of significantly low total cholesterol levels is a reliable 
and easy test for ABL/FHBL (8,18,20).  To differentiate between ABL and biallelic FHBL, 
testing in the parents’ probands (who are heterozygous for mutations in MTTP and 
APOB, respectively) is required as in ABL the parents are almost always asymptomatic 
while in FHBL, heterozygous individuals have approximately 30% of LDL-c levels 
consistent with a codominant inheritance pattern (47). 
Chylomicron retention disease is a disorder that shares many clinical features with ABL 
and biallelic FHBD. However, retinopathy has not been reported, acanthocytosis is less 
commonly observed, and neuromuscular manifestations are milder (45). In addition, the 







total cholesterol levels are above 50 mg/dl, and LDL and apo B levels are very low but 
higher than in ABL (47). 
Mutations in PCSK9 and ANGPTL3 lead to a co-dominantly inherited familial 
hypobetalipoproteinemia and a recessively inherited familial combined hypolipidemia, 
respectively. Probands present with reduced lipoprotein levels. However, they are often 
not clinically diagnosed because of an asymptomatic phenotype (45,48). Cases of severe 
fatty liver in combined hypolipidemia caused by ANGPTL3 mutations have been 
described (29). 
The probands fasting lipid profile study allows the exclusion of Friedrich's ataxia and 
McLeod neuroacanthocytosis syndrome diagnoses. In these disorders, patients have a 
standard lipid profile and no symptoms of fat-soluble vitamin deficiency (8).  
In the end, If the clinical profile of the proband suggests the diagnosis of ABL, the 
definitive diagnosis can be established by genetic sequencing. Next-generation 
sequencing (NGS) strategies are currently used to identify mutations in the DNA. 
Relevant genes related to ABL, FHBL, and other hypobetalipoproteinemias (MTTP, 
SAR1B, APOB, PCSK9, and ANGPTL3) or other genes for differential diagnoses can be 
sequenced by multi-gene panel testing to identify pathogenic variants. The presence of 
biallelic homozygous or compound heterozygous mutations in MTTP confirms the 
diagnosis (8,49). 
To summarize, a precise clinical and differential diagnosis would lead to a suspicion of a 
type of hypobetalipoproteinemia. However, the observation of clinical manifestations is 
not sufficient to distinguish between ABL and homozygous FHBL as they are 
phenotypically indistinguishable. The analysis of the lipidic profile on the parents of the 
proband is a practical test to differentiate between the two, as it typically shows, in the 
case of ABL, normal lipid values consistent with autosomal recessive inheritance, and 
for the case of HHBL, reduced normal levels of B-lps consistent with autosomal 
codominant inheritance. Finally, molecular genetic testing is the only way to obtain a 
definitive diagnosis: ABL patients have biallelic mutations on the MTTP gene that lead 











After diagnosing abetalipoproteinemia, patients' monitoring is required to identify new 
manifestations, control the evolution of the disease, and improve the therapeutic 
regimen according to the routinary analytical tests of fat-soluble vitamins and lipids. 
Abetalipoproteinemia is a disease associated with high morbidity that affects a wide 
range of organ systems. Therefore, an interprofessional healthcare team integrated of 
professionals specialized in different disciplines for its management and treatment is 
required to have the best outcome (26).  
The health professionals that participate in the monitorization and treatment of patients 
with abetalipoproteinemia (or familial hypobetalipoproteinemia FHBL) are: 
Patient's primary care clinician/ Pediatrician: Identifies the first symptoms that lead to 
a diagnosis of ABL. Controls the height and weight in every visit are needed. May refer 
to the gastroenterologist. 
Gastroenterologist: Has an essential role in determining ABL. Observes the 
gastrointestinal manifestations, as they are the most prevalent, especially during 
infancy. It detects fat in the stool (steatorrhea). Performs analytical test to determine 
serum lipid profile (LDL-c, HDL-c, and total cholesterol; triglyceride; Apo-B; Apo-A-I; 
serum concentrations of fat-soluble vitamins (A, D, E, K); and liver transaminases and 
bilirubin levels.  Performs endoscopy or abdominal ultrasound to evaluate for 
steatohepatitis, fibrosis, or cirrhosis. Refers to a nutritionist to provide dietary advice 
about a low-fat diet (8,50). 
Neurologist: Assesses the patient's neurological function to prevent or cease 
progressive axonopathy leading to spinocerebellar degeneration and ataxia.  Proper 
control of vitamin E is required. If needed, performs an MRI of the spinocerebellar region 
to detect possible degeneration (8,51). 
Ophthalmologist: Performs funduscopic examination,  monitors visual acuity and bone 
mineral density to detect night or color vision loss, suggesting an atypical type of retinitis 
pigmentosa (4,8).  
Dietitian/ Nutritionist: Assesses the patient for failure to thrive and malabsorption of 










Hematologist: Identifies acanthotic red blood cells and evaluates for anemia, hemolysis, 
and other hematological findings. It also controls the international normalized ratio 
(INR) as a prolongation of INR may increase the risk of bleeding and performs a complete 
blood count (CBC) (4,8). 
Pharmacist: detects adverse effects or problems related to the pharmacological 
treatment (vitamin supplements and other medication to treat particular clinical 
manifestations like anemia). Moreover, it ensures that the members of the 
interprofessional team and the patient are aware of the medications that may increase 
or reduce vitamin levels to avoid such interactions (52).     
Endocrinologist: Monitoring hypothyroidism is not a very common manifestation, but 
monitoring thyroid function and evaluating thyroid-stimulating hormone (TSH) levels 
should be done once a year (4). 
Clinical geneticist or genetic counselor: provides the proband and its family with 
information regarding the nature and the mode of inheritance of the genetic disorder. 
Performs genetic testing to proband and parents to distinguish between ABL and FHBL, 
as the parents of a patient with ABL are obligate heterozygotes for a pathogenic variant 
of MTTP gene, and tests other relatives for early detection and implementation of 
treatment in affected individuals. Siblings of the proband may also be tested, as they 
have a 25% chance of being affected, 50% of them being an asymptomatic carrier 
(obligate heterozygotes), and 25% of not carrying the mutation (8). The offspring of the 
proband will be obligate heterozygotes if the other parent is not a carrier; if the partner 
is an obligate heterozygote, the offspring has a 50% chance of being affected; and if both 
are bi-allelic carriers, all their kids will be affected.  
The interprofessional team may include other members like social workers, nurses, 
psychologists, physiotherapists, etc. 
Lifetime clinical follow-up is almost compulsory to ensure the expected evolution of the 
patient. The focus of the follow-up should be monitoring the growth of children and 
preventing secondary complications by controlling the clinical state of the patient, 
including coagulation and hepatic function. As individuals grow older, neurological, 
ophthalmic, and bone mineral density studies are added to monitor for 











Table 2 outlines a follow-up strategy for patients affected with ABL. 
Table 2:  Abetalipoproteinemia follow-up after diagnosis. Adapted from: 
Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for 
diagnosis and management (4). 
Clinical evaluation  Laboratory investigations 
every 6–12 months every year 
General Height/weight for 



























Hepatic Aspartate aminotransferase 
Alanine aminotransferase  
Alkaline phosphatase 
Gamma-glutamyl transferase  






















Vitamins Vitamin A (Beta-carotene) 
 Vitamin D (25-OH D) 
 Vitamin E 
 Vitamin B9 (Folate) 









Bone mineral density via DXA 
Every 6–12 months 
Every 6–12 months 
Every 3 years 
Every 3 years 




Other TSH  
 Calcium 
 Phosphate 
 Uric acid 
*lipid profile must be performed at baseline, however annual follow-up is not needed as lipid 












It is difficult to make an accurate prognosis of the disease due to its rarity. There are just 
over 100 cases described in the scientific literature on this pathology, many of which are 
very recent, so it is not known what the long-term evolution of the patient will be. 
The prognosis can differ significantly depending on the age of diagnosis, the nature of 
the pathological variant of the MTTP gene, and the diet followed. These factors greatly 
influence the evolution of the disease and the response to treatment. 
Early diagnosis and implementation of treatment that includes at least a low-fat diet and 
high vitamin supplements, generally allow the patient to have a favorable prognosis and 
live a life without significant complications associated with the disease. Nevertheless, 
without treatment, the disease has high morbidity. Furthermore, it decreases the 
patient's quality of life and lifespan, with reported deaths before the third decade of life 
due to severe neuromyopathy (8). 
Patients that initiated treatment later in life usually present with some neuromuscular 
and ophthalmic manifestations, like ataxia, dysarthria, and atypical retinitis pigmentosa. 
Treatment with high doses of vitamin E and A can arrest progression or prevent further 
complications but cannot reverse the current symptomatology (34). 
Currently, there is still a great lack of knowledge regarding the severity of the disorder 
depending on the mutations of MTTP. Although all pathological variants result in a non-
functional MTTP protein, the clinical phenotype is not always similar, as there are 
complicated cases of atypical ABL not improving with treatment. In addition, cases have 
been reported of patients who died in the first few months of life from malnutrition as 
a result of diarrhea, even with dietary and pharmacological interventions (53).  
4.7. TREATMENT 
Currently, no specific treatment for abetalipoproteinemia exists, and therapy is based 
only on treating and preventing associated symptomatology. The mainstay treatment 
involves a strict low-fat diet and exogenous administration of fat-soluble vitamins (A, D, 
K, E) lifetime. Supplementation of other vitamins (vitamin B12, folate), nutrients 
(polyunsaturated EFAs, MCT), minerals (iron, calcium), or hormones (THR) may be 
considered depending on the symptoms the patient presents. Non-pharmacological 
therapy (e.g., organ transplantation in hepatic fibrosis and cirrhosis or physical 
rehabilitation in ataxia) may be recommended when results are unsatisfactory with the 







Table 3 outlines the therapeutical management of the most significant clinical 
manifestations in individuals with abetalipoproteinemia. 
Table 3: Treatment of clinical manifestations in abetalipoproteinemia. Adapted from: 
Abetalipoproteinemia (8). 
Manifestation/ Concern Treatment 
GENERAL 
Deficiency of fat- soluble 
vitamins 
- Vitamin A (100-400 IU/kg/day) 
- Vitamin D (800-1,200 IU/day) 
- Vitamin E (100-300 IU/kg/day)  
- Vitamin K (5-35 mg/week)  
*Oral vitamin supplementation; parenteral administration is not necessary 
Growth deficiency - Ensure adequate caloric intake 
- Medium-chain triglycerides (MCT) supplementation  
GASTROINTESTINAL 
Steatorrhea - Low-fat diet (10%-20% of total calories)  
- Oral EFAs (1-2 tsp/day of oils rich in  polyunsaturated fatty acids (e.g., 
soybean or olive oil) as tolerated) 
HEPATIC 
Fatty liver - Restriction of dietary fat 
Hepatic fibrosis/ Cirrhosis - Liver transplantation may be considered 
*suspend MCT suppl. (elevates risk of hepatic fibrosis and cirrhosis) 
HEMATOLOGICAL  
Anemia - Iron or vitamin B12  
Increased INR - Vitamin K supplementation  
NEUROLOGICAL  
Dysarthria - Speech and language therapy  
- Prophylactic early vitamin E supplementation. 
Ataxia - High-dose vitamin E supplementation for prevention or delay of 
neurological dysfunction. 
- Intensive physical rehabilitation or physiotherapy 
- Fall prevention (canes, walkers, wheelchairs) 
- Weight control (obesity exacerbates mobility difficulties) 
- An interdisciplinary team formed by a neurologist, physiatrist, physical 
therapist, and occupational therapist will provide the best treatment 
OPHTALMOLOGICAL 
Abnormal visual acuity/ 
Retinopathy 
Vitamin A + Vitamin E supplementation can arrest progression of visual 
impairment and prevent development of eye complications. 
Ptosis, ophthalmoplegia Prevention with vitamin E supplementation  
OTHERS 
Hypothyroidism Standard treatment w/thyroid hormone replacement 








A restrictive-fat diet is essential as diarrhea, steatorrhea and other gastrointestinal 
problems occur due to the ingestion of lipids that the body is unable to absorb. These 
clinical manifestations often cause severe malnutrition in the affected individuals, which 
in some cases can even lead to death. Sometimes there are patients who, despite not 
being initially diagnosed, have found that a decrease in the consumption of fatty foods 
improves their gastrointestinal status, so they naturally follow a low-fat diet to avoid 
unpleasant symptoms. 
The recommended regimen in patients with ABL is a reduction in fat consumption up to 
30% of total caloric intake (preferably < 20%) as well as long-chain fatty acids. In 
addition, one or two teaspoons (tsp) of oil rich in polyunsaturated fatty acids are 
recommended to ensure intake of essential fatty acids (EFAs) (4). 
Bearing in mind that lipids provide around 9 calories/gram as opposed to carbohydrates 
and proteins, which provide approximately 4 kcal/g, the established diet should suffice 
the energetic needs of the patient and ensure that the individual receives the 
appropriate caloric intake for its age and weight in order to avert growth deficiency. 
Medium-chain triglyceride oil (MCT oil) can be added as a supplement in food if 
malnourishment persists to assist with weight gain in children. These TGs are not 
transported by chylomicrons but are albumin-bound, so they can be absorbed and reach 
the liver in ABL patients (54).  However, prolonged consumption of MCT is not 
recommended due to the potential risk of hepatic steatosis and cirrhosis (55). 
4.7.2. PHARMACOLOGICAL TREATMENT  
Vitamin E  
Vitamin E is a potent lipid-soluble antioxidant obtained exclusively from diet and 
transported from the intestine to the liver in apo B-containing lipoproteins. In ABL this 
vitamin cannot be transported, and consequently serum levels are not detectable. 
Therefore, massive vitamin supplementation is needed at very high doses to meet the 
needs (56). 
It is vital to initiate treatment with vitamin E as soon as possible in order to prevent, or 
delay, neuromuscular manifestations, such as peripheral neuropathy or spinocerebellar 
ataxia mimicking Friedreich's ataxia, and ophthalmological manifestations, such as 
ptosis (36). Treatment may improve neurological and motor disturbances when the 
condition is not severe, but usually does not recover the patient’s initial state. 
Administration of vitamin E alone does not improve retinal and field vision function (57). 








Vitamin E is usually given as dl-alpha-tocopheryl acetate, which contains higher vitamin 
activity and is in the form of acetate, which is an ester, to bring greater stability. Very 
high doses are administered: between 50-300 IU/kg/day in adults and children over 10 
years of age (34). It is preferably administered orally as capsules or solution (54,60) since 
parenteral administration has been reported to result in hepatic steatosis (4) and skin 
necrosis at the site of the injection (54). Despite large dose supplementation, vitamin E 
levels are only marginally increased (8). Dosing is preferably done according to the 
vitamin E/serum cholesterol ratio instead of vitamin E serum levels as it is not a reliable 
indicator of real vitamin E levels (61). 
Tocopherolsan, another form of vitamin E, has been studied and found to have a lower 
bioavailability than alpha-tocopherol (62). 
Vitamin A 
In contrast to Vitamin E, Vitamin A (retinol) has been found to have an alternative 
pathway of transportation and absorption by retinol-binding proteins instead of only the 
chylomicron route (63). It makes it possible for affected individuals to achieve normal 
serum levels by high-dose retinol supplementation (100–400 IU/kg/day). Combination 
with vitamin E is helpful to arrest or prevent ophthalmic complications such as atypical 
retinitis pigmentosa, decreased night or color vision, or blindness (4). 
Titration according to serum beta-carotene concentrations allows correct dosing of 
retinol (34). Toxicity due to vitamin A supplementation has been observed in one case 
where a patient developed papilledema a few days after beginning treatment despite 
regular vitamin A levels (14). 
Vitamin D 
Vitamin D deficiency is not always observed in patients with ABL. However, low levels of 
25-OH vitamin D and serum-ionized calcium have been reported. Subsequently, cases of 
rickets secondary to vitamin D or calcium malabsorption have been reported (39,64). To 
avoid the risk of bone abnormalities, prophylactic early administration of doses between 
800-1,200 IU/day in all patients is recommended (4,65). 
Abundant sun exposure is recommended to raise vitamin D concentrations.  
Vitamin K 
Malabsorption of vitamin K can increase international normalized ratio (INR) and 
elevated prothrombin time in ABL. Monitoring of clotting parameters (INR, APTT, PT, 
and fibrinogen levels) is necessary to control and manage abnormal bleeding and 
coagulopathy. Intracranial hemorrhage (66) and severe upper gastrointestinal bleeding 
cases (67) have been reported. Oral doses of 5-35mg/week of vitamin K 








Iron, Folate, and Vitamin B12 
Anemia in affected individuals is caused by deficiencies in micronutrients (iron, folate 
(vitamin B9), or vitamin B12) due to inadequate lipid absorption. It can be exacerbated 
by hemolysis that results from accelerated lipid peroxidation secondary to vitamin E 
deficiency (69). 
Mild anemia often does not require treatment. However, in some cases, nutritional 
supplementation of iron, folate, or cyanocobalamin may be needed (34). 
Thyroid Hormone Replacement 
Although rare, cases of hypothyroidism have been reported in patients with ABL, so TSH 
levels should be evaluated at least once. If abnormal thyroid function is observed, it is 
recommended to establish standard treatment with thyroid hormone replacement 
(levothyroxine) (38,70). 
4.7.3. PREGNANCY IN WOMEN WITH ABL 
Stricter monitoring of fat-soluble vitamin levels should be performed in women who are 
planning to conceive or are already pregnant since it will affect the fetus directly, 
especially vitamin A, which is teratogenic, and an overdose can lead to malformations 
in the fetus (61). Nonetheless, it is not advisable to interrupt treatment as it would 
increase morbidity of the mother, including the risk of developing ophthalmic 
pathologies and preeclampsia. For example, a case report of a mother with ABL who had 
stopped taking vitamin A during pregnancy had her child born prematurely with 
significant ophthalmic abnormalities (bilateral colobomata) (71). However, it is prudent 
to reduce the dose by half to avoid possible teratogenic effects in the fetus (8). 
As for vitamin D, a deficiency in the fetus can cause hypocalcemia and rickets, while an 
overdose may lead to a delay in fetal growth and calcium deposits in various organs, so 
it is essential to maintain vitamin D concentrations in the normal range. 
Whereas vitamin E does not usually cause problems in the fetus when it is in excess, a 
deficiency triggers neuromuscular and ophthalmic complications in the mother and low 
birth weight in the child. 
Lastly, there are no documented fetal risks of excess vitamin K supplementation. 
Nevertheless, mothers should take vitamin K to avoid increased INR leading to abnormal 
bleeding and hemorrhages, not only of the patient but also of the child she is bearing. 
Spontaneous abortions may also occur (71). 
The benefits-risk balance evaluation for the affected mother and her child should be 
done to decide whether to continue or modify the posology of the treatment with fat-







4.7.4. NON-PHARMACOLOGICAL TREATMENT  
Usually, with early diagnosis and treatment, critical complications can be avoided. 
Sometimes, when the symptomatology is more severe, implementation of a low-fat diet 
and treatment with oral or parenteral vitamin and nutrient supplementation is not 
enough. 
In hepatic fibrosis or cirrhosis, liver transplantation may be taken into account. 
Dysarthria is rare with vitamin E supplementation. Treatment includes speech and 
language therapy. 
Ataxia can be prevented or decelerated with early treatment with vitamin E. Depending 
on the degree of the symptomatology, physical rehabilitation or physiotherapy, fall 
prevention, weight control, etc. may be advantageous to improve the physical state and 
patient’s quality of life (8). 
4.7.5. VISION OF FUTURE TREATMENT 
There is currently no specific therapy for abetalipoproteinemia, as the only available 
therapy consists of treatment or prevention of symptoms, so there is no cure. However, 
in the last few years, gene therapy has gained interest as a new approach to treat 
individuals with genetic disorders.  
In a study made by Liu et al. using induced pluripotent stem cells (iPCSs) generated from 
a patient with ABL homozygous for a missense mutation (MTTPR46G) and differentiated 
into hepatocytes and cardiomyocytes, it was observed that these cells had defects due 
to the pathogenic variant. The mutation was corrected by CRISPR/Cas9 gene edition, 
and the phenotype was reversed (72). There is a possibility that in the future, this 
technique will be used as gene therapy to treat ABL and other genetic pathologies by 
eradicating the mutation that triggers the disease. Clinical studies have already begun 
introducing CRISPR/Cas9 therapy directly into the body to treat Leber’s congenital 
amaurosis 10 (LCA10), a genetic disease that causes blindness in childhood (73).  
4.7.6. APPLICATION OF ABETALIPOPROTEINEMIA: LOMITAPIDE 
The study of the etiology of ABL has revealed the critical role of the microsomal 
triglyceride transfer protein in the assembly and trafficking of apoB-containing 
lipoproteins. Mutations in the MTTP gene in ABL prevent the entry of cholesterol, 
triglycerides, and other lipids into lipoproteins and their transport to the liver and gut. 
This knowledge has been applied to develop the active ingredient lomitapide, which is 
marketed in the form of hard capsules under the trade name Lojuxta®. MTTP is the 
therapeutic target of this active principle that inhibits its activity. It is used in the 
treatment of homozygous familial hypercholesterolemia (HoFB) to lower blood LDL 
cholesterol levels. Treatment is initiated at a dose of 5 mg/day, which gradually 







given along with other medications to lower blood non-HDL cholesterol in a low-lipid 
diet (74,75). 
In an open-label phase III clinical trial lomitapide’s efficacy was confirmed. However, 
many hepatic and gastrointestinal adverse effects were observed as the liver, and the 
intestines are the organs where the drug mainly acts. Most participants developed 
hepatic steatosis as well as increased liver enzymes alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) levels. Because it is a recently commercialized drug, 
the long-term effects are still unknown.  
A reduction in the absorption of fat-soluble vitamins and nutrients has been observed. 
Therefore, vitamin E and EPAs supplementation may be necessary. 
Use of the drug in patients with moderately or severely reduced liver function or 
pregnant women must be avoided. Moreover, no study has been performed on children 
























The bibliographic research carried out in this work has allowed me to draw the following 
conclusions: 
• Abetalipoproteinemia is an extremely rare disease inherited in an autosomal 
recessive pattern, caused by inhibitory mutations in the MTTP gene that lead to the 
formation of truncated non-active MTTP chaperones. The inability of MTTP to play 
its role in the transportation and assembly of apo B-containing lipoproteins 
incapacitates the affected person to absorb lipids and fat-soluble vitamins from the 
diet.   
• Abetalipoproteinemia is a multiorgan disorder. It affects the following systems: 
gastrointestinal (steatorrhea, diarrhea, fat malabsorption), hepatic (non-alcoholic 
fatty liver, hepatic steatosis, cirrhosis), hematologic (acanthocytosis, elevated INR, 
anemia), neuromuscular (spinocerebellar ataxia, dysarthria, peripheral neuropathy), 
ophthalmic (atypical retinitis pigmentosa, progressive blindness), cardiac 
(cardiomyopathy), osseous (failure to thrive, rickets), and endocrine 
(hypothyroidism) systems. From the approximately 100 cases reported in the 
literature worldwide, a multitude of clinical manifestations have been described, 
some of them in very few patients. Therefore, it makes it difficult to discern if the 
manifestations are associated with ABL or if they have a different etiology, as 
correlation does not always imply causation. 
• To achieve the best outcome for the affected individuals, it is crucial the 
participation of an interprofessional team to assist the patient in all clinical aspects. 
A quick diagnosis enables the early initiation of fat-soluble vitamins A, D, K, and E 
treatment and a lipid-restrictive diet, which reduces enormously the risk of suffering 
from ataxia, atypical retinitis pigmentosa, and other manifestations and improves 
the quality of life of the patient.  
• Research and investigation of rare diseases should be promoted for two reasons: 
- To allow affected individuals to live with a minimum of impairments by reducing 
morbidity and mortality and improving patients' quality of life. Moreover, the study 
of the particular cases reported of abetalipoproteinemia to improve the clinical 
picture of the patients led to the implementation of a guideline for the follow-up 
and treatment of the disorder. 
 - The study of rare genetic diseases often permits a better understanding of human 
physiology and pathophysiology. For example, while carrying investigations about 
abetalipoproteinemia, the function of MTTP and the consequences of its inhibition 
were discovered, which served as a target for the development of the active 







hypercholesterolemia. Furthermore, the importance of vitamin E in neurological 
function and how its deficiency causes neurological degeneration exhibited as loss 
of tendon reflexes, ataxia, etc. have only been revealed after studying 
abetalipoproteinemia. 
• Soon, individualized gene therapy will be key in medicine, especially for treating 
Mendelian genetic diseases. From the implementation of next-generation 
sequencing methods (NGS) for the diagnosis of diseases caused by genetic mutations 
until the present study of CRISPR / Cas9 gene edition to treat genetic-based 
disorders, the role of genetic engineering will be crucial. It cannot be ruled out that 
specific treatment for ABL could be designed if more capital is invested in research. 
However, because, in most cases, a low-lipid diet and vitamin and nutrient 
supplementation make it possible to prevent most of the negative manifestations, 
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COMPARISON OF A REAL CASE WITH THE RECOMMENDED TREATMENT 
This bibliographic research allowed me to know more in-depth about the current 
treatment of abetalipoproteinemia. There, I compare a framework for the treatment of 
ABL with a real case. 
R.K.A. is a patient who was diagnosed with ABL at the age of 1 year and 3 months. He is 
following a fat-poor diet that has been a little less restrictive through the years, but lipids 
are still < 20 % of his daily caloric intake. He also ingests 1 tsp of olive oil 
(polyunsaturated fatty acids) and approximately 15 ml of MCT oil daily. Currently, the 
treatment also includes 80 mg of ferrous sulfate per day because of mild anemia. Table 
A1 compares the fat-soluble vitaminic supplementation the patient receives with the 
recommended treatment. 
Table A1: Comparison of the proband’s treatment with the recommended treatment. 
            PROBAND’S TREATMENT                 RECOMMENDED TREATMENT 
Oral fat-soluble vitamins Dose Oral fat-soluble vitamins Dose 
Vitamin E 1220 IU/day Vitamin E 50–300 IU/kg/day 
Vitamin A 5000 IU/day Vitamin A 100–400 IU/kg/day 
Vitamin D 800 IU/day Vitamin D 800–1200 IU/day 
Vitamin K 18 mg/week Vitamin K 5–35 mg/week 
 
The proband lives in Catalonia, Spain. Table A2 shows the specific treatment he follows: 
drugs commercialized in Spain he takes, from which trading house, the pharmaceutical 
form, and the posology. 
Table A2: Specific treatment for ABL of proband R.K.A. 
DRUG TRADING HOUSE PHARMACEUTICAL FORM POSOLOGY 
Auxina E-400 IU CHIESI ESPAÑA, S.A.U.    Soft capsules 1 capsule/8h (1-1-1) 
 
Auxina A+E CHIESI ESPAÑA, S.A.U.    Soft capsules 1 capsule/12h (1-0-1) 
 




   Oral solution - 0.2 ml/24h: 
5 days/week (0-0-1) 
- 0.2ml/12h: 
2 days/week (1-0-1) 
Vitamin D3 2,000 UI/ml Kern Pharma, S.L.   Oral solution 0.4 ml/24h (0-0-1) 
Tardyferon 80 mg Pierre fabre ibérica, S.A.   Film-coated tablet 1 tablet/24h (1-0-0) 
 
